[{"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-001", "question": "A 45-year-old man with a history of relapsing-remitting multiple sclerosis presents with acute onset of bilateral leg weakness and urinary retention. MRI shows a new T2-hyperintense lesion at T10 with gadolinium enhancement. Despite high-dose intravenous methylprednisolone, symptoms worsen over 48 hours. CSF analysis reveals elevated IgG index and oligoclonal bands. What is the most appropriate next step in management?", "options": ["Initiate plasma exchange", "Administer rituximab", "Start fingolimod", "Perform lumbar puncture for repeat CSF analysis", "Switch to natalizumab"], "answer": "A", "answer_index": 0, "explanation": "Plasma exchange is the most appropriate next step for severe acute demyelinating attacks unresponsive to corticosteroids in multiple sclerosis, as it rapidly removes circulating autoantibodies and inflammatory mediators. Rituximab and natalizumab are disease-modifying therapies not indicated for acute management, while fingolimod is contraindicated in active inflammation; repeat CSF analysis is unnecessary with established diagnosis.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known relapsing-remitting MS; acute transverse myelitis picture (bilateral leg weakness, urinary retention) with enhancing T10 lesion; lack of improvement and clinical worsening after high-dose IV methylprednisolone over 48 hours. This clearly describes a severe acute MS relapse refractory to first-line steroid therapy. The best-supported next step in guidelines is escalation to plasma exchange.\\nOption A (plasma exchange) is appropriate as second-line therapy for steroid-refractory severe acute demyelinating attacks. Options B, C, and E (rituximab, fingolimod, natalizumab) are disease-modifying therapies for long-term relapse prevention rather than acute attack treatment; none addresses the urgent deterioration. Option D (repeat CSF) is unnecessary: diagnosis is already established and CSF would not change immediate management.\\nMain logical issues: None significant; timeframe (48 hours) is within typical practice to recognize steroid non-response in a severe attack, and no alternative option offers comparable acute benefit.\\nMain medical accuracy issues: Minor—\\\"fingolimod is contraindicated in active inflammation\\\" is oversimplified (DMF can be started after stabilization), but not central to key.\\nMinimal fix: Slightly rephrase explanation to state that fingolimod is not used for acute relapse treatment, rather than “contraindicated in active inflammation.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known relapsing-remitting MS; acute transverse myelitis picture (bilateral leg weakness, urinary retention) with enhancing T10 lesion; lack of improvement and clinical worsening after high-dose IV methylprednisolone over 48 hours. This clearly describes a severe acute MS relapse refractory to first-line steroid therapy. The best-supported next step in guidelines is escalation to plasma exchange.\nOption A (plasma exchange) is appropriate as second-line therapy for steroid-refractory severe acute demyelinating attacks. Options B, C, and E (rituximab, fingolimod, natalizumab) are disease-modifying therapies for long-term relapse prevention rather than acute attack treatment; none addresses the urgent deterioration. Option D (repeat CSF) is unnecessary: diagnosis is already established and CSF would not change immediate management.\nMain logical issues: None significant; timeframe (48 hours) is within typical practice to recognize steroid non-response in a severe attack, and no alternative option offers comparable acute benefit.\nMain medical accuracy issues: Minor—\"fingolimod is contraindicated in active inflammation\" is oversimplified (DMF can be started after stabilization), but not central to key.\nMinimal fix: Slightly rephrase explanation to state that fingolimod is not used for acute relapse treatment, rather than “contraindicated in active inflammation.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-002", "question": "A 62-year-old woman with incomplete tetraplegia from a C5 spinal cord injury undergoes inpatient rehabilitation. She develops orthostatic hypotension during tilt table training, with blood pressure dropping from 120/80 mmHg supine to 85/50 mmHg at 60 degrees. Heart rate increases minimally. Autonomic testing shows absent sympathetic skin response below the lesion. What is the most effective pharmacologic intervention to facilitate upright tolerance?", "options": ["Midodrine", "Fludrocortisone", "Propranolol", "Clonidine", "Ephedrine"], "answer": "A", "answer_index": 0, "explanation": "Midodrine, an alpha-1 agonist, is the most effective for neurogenic orthostatic hypotension in spinal cord injury by promoting vasoconstriction without significant supine hypertension risk. Fludrocortisone causes fluid retention but risks edema; propranolol and clonidine may worsen hypotension, while ephedrine is less selective and has more side effects.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: chronic C5 spinal cord injury with incomplete tetraplegia; orthostatic hypotension during tilt-table training with large BP drop and minimal HR increase (neurogenic orthostatic hypotension); autonomic testing showing absent sympathetic skin response below the lesion, confirming impaired sympathetic vasoconstriction. The question asks for the most effective pharmacologic intervention to improve upright tolerance.\\n\\nMidodrine, a peripherally acting alpha-1 agonist, directly increases peripheral vascular resistance and is first-line for neurogenic orthostatic hypotension, including in spinal cord injury. It is appropriately favored over fludrocortisone, which expands volume but is generally less effective and carries edema and supine hypertension risks. Propranolol and clonidine would likely worsen hypotension by reducing sympathetic tone or heart rate. Ephedrine is less selective, shorter-acting, and has more CNS/cardiac side effects, so is not the best choice.\\n\\nMain issues: The explanation slightly overstates midodrine’s lack of supine hypertension risk; in reality, it can cause supine hypertension and requires caution, but the relative ranking versus alternatives is still correct.\\n\\nMinimal fix: Qualify the explanation to state that midodrine is first-line but still carries a risk of supine hypertension requiring dosing and positioning precautions, rather than “without significant supine hypertension risk.”\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: chronic C5 spinal cord injury with incomplete tetraplegia; orthostatic hypotension during tilt-table training with large BP drop and minimal HR increase (neurogenic orthostatic hypotension); autonomic testing showing absent sympathetic skin response below the lesion, confirming impaired sympathetic vasoconstriction. The question asks for the most effective pharmacologic intervention to improve upright tolerance.\n\nMidodrine, a peripherally acting alpha-1 agonist, directly increases peripheral vascular resistance and is first-line for neurogenic orthostatic hypotension, including in spinal cord injury. It is appropriately favored over fludrocortisone, which expands volume but is generally less effective and carries edema and supine hypertension risks. Propranolol and clonidine would likely worsen hypotension by reducing sympathetic tone or heart rate. Ephedrine is less selective, shorter-acting, and has more CNS/cardiac side effects, so is not the best choice.\n\nMain issues: The explanation slightly overstates midodrine’s lack of supine hypertension risk; in reality, it can cause supine hypertension and requires caution, but the relative ranking versus alternatives is still correct.\n\nMinimal fix: Qualify the explanation to state that midodrine is first-line but still carries a risk of supine hypertension requiring dosing and positioning precautions, rather than “without significant supine hypertension risk.”", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-003", "question": "A 28-year-old woman presents with recurrent episodes of vertigo, tinnitus, and fluctuating hearing loss, now with superimposed gait instability. MRI reveals bilateral vestibular schwannomas and a spinal ependymoma. Genetic testing confirms NF2 mutation. She develops progressive bilateral facial weakness. What is the most appropriate targeted therapy to consider for tumor stabilization?", "options": ["Bevacizumab", "Everolimus", "Crizotinib", "Trametinib", "Sorafenib"], "answer": "A", "answer_index": 0, "explanation": "Bevacizumab, a VEGF inhibitor, is the most appropriate for NF2-associated schwannomas by reducing tumor vascularity and stabilizing growth, with evidence from clinical trials showing hearing preservation. Everolimus targets mTOR but lacks specificity for NF2; crizotinib, trametinib, and sorafenib are not indicated for this condition and target unrelated pathways.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young adult with bilateral vestibular schwannomas, spinal ependymoma, and confirmed NF2 mutation; symptomatic progression with hearing loss and facial weakness; question asks for “most appropriate targeted therapy…for tumor stabilization.” In current practice, bevacizumab (VEGF inhibitor) has the best evidence for NF2-associated vestibular schwannomas, including tumor shrinkage and hearing preservation in a subset of patients. None of the other listed agents have established or preferential roles in NF2-related schwannomas.\\nLogical issues: The stem is clear, includes the specific genetic diagnosis (NF2), and asks a focused management question. The options are clearly distinct targeted agents with different mechanisms and indications; only bevacizumab fits accepted evidence for this condition. No significant ambiguity or overlapping indications exist among the options.\\nMedical accuracy issues: The rationale is consistent with the literature on bevacizumab for NF2 vestibular schwannomas. The brief comments about everolimus and the kinase/MEK inhibitors are directionally correct; while there is some investigational interest in mTOR/other pathways, these are not standard or “most appropriate” choices.\\nMinimal fix: Optionally specify “evidence-based systemic therapy” in the stem to emphasize the therapeutic context over surgical/radiosurgical options.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young adult with bilateral vestibular schwannomas, spinal ependymoma, and confirmed NF2 mutation; symptomatic progression with hearing loss and facial weakness; question asks for “most appropriate targeted therapy…for tumor stabilization.” In current practice, bevacizumab (VEGF inhibitor) has the best evidence for NF2-associated vestibular schwannomas, including tumor shrinkage and hearing preservation in a subset of patients. None of the other listed agents have established or preferential roles in NF2-related schwannomas.\nLogical issues: The stem is clear, includes the specific genetic diagnosis (NF2), and asks a focused management question. The options are clearly distinct targeted agents with different mechanisms and indications; only bevacizumab fits accepted evidence for this condition. No significant ambiguity or overlapping indications exist among the options.\nMedical accuracy issues: The rationale is consistent with the literature on bevacizumab for NF2 vestibular schwannomas. The brief comments about everolimus and the kinase/MEK inhibitors are directionally correct; while there is some investigational interest in mTOR/other pathways, these are not standard or “most appropriate” choices.\nMinimal fix: Optionally specify “evidence-based systemic therapy” in the stem to emphasize the therapeutic context over surgical/radiosurgical options.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251225T231536524Z_grok-4-0709_seed133", "question_id": "20251225T231536524Z_grok-4-0709_seed133-004", "question": "A 55-year-old man with diabetic amyotrophy presents for outpatient rehabilitation with severe proximal leg weakness and pain. Electromyography shows denervation in the L2-L4 myotomes. Despite optimized glycemic control, he has persistent muscle atrophy. What is the most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy?", "options": ["Intravenous immunoglobulin", "Pyridostigmine", "Gabapentin", "Corticosteroids", "Plasmapheresis"], "answer": "A", "answer_index": 0, "explanation": "Intravenous immunoglobulin has shown benefit in diabetic amyotrophy by modulating autoimmune-mediated nerve damage, leading to improved strength and pain control in refractory cases. Corticosteroids risk worsening diabetes; pyridostigmine is for myasthenia, gabapentin addresses pain but not weakness, and plasmapheresis lacks supporting evidence.", "generator_model": "grok-4-0709", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Physical Medicine and Rehabilitation", "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: 55-year-old man, diabetic amyotrophy (lumbosacral radiculoplexus neuropathy) with L2–L4 denervation, severe proximal weakness and pain, persistent atrophy despite glycemic control and standard PT; asking for “most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy.”\\nMain logical issues: For diabetic lumbosacral radiculoplexus neuropathy, the evidence for any immunotherapy (IVIG, corticosteroids, plasmapheresis) is limited and mixed. Some small, low-quality studies/case series suggest possible benefit of steroids and IVIG; neither clearly has superior or robust evidence. The prompt’s phrase “most evidence-based” is therefore problematic: pain agents like gabapentin have solid evidence for symptom control (though not strength), and both IVIG and steroids are at best experimental/off-label with comparable or weaker evidence. The explanation’s categorical claim that IVIG “has shown benefit” and that plasmapheresis “lacks supporting evidence” oversimplifies a generally low-evidence area, making A not a clearly superior choice to D, and arguably not more evidence-based than optimizing neuropathic pain management.\\nMain medical accuracy issues: Overstates IVIG evidence and understates uncertainty around all immunotherapies.\\nMinimal fix: Reframe question as “Which investigational immunomodulatory therapy has been reported in small case series to improve pain and strength…?” and keep IVIG as key, or change key/explanation to emphasize limited evidence and focus on pain control (gabapentin).\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: 55-year-old man, diabetic amyotrophy (lumbosacral radiculoplexus neuropathy) with L2–L4 denervation, severe proximal weakness and pain, persistent atrophy despite glycemic control and standard PT; asking for “most evidence-based adjunctive therapy to enhance functional recovery beyond standard physical therapy.”\nMain logical issues: For diabetic lumbosacral radiculoplexus neuropathy, the evidence for any immunotherapy (IVIG, corticosteroids, plasmapheresis) is limited and mixed. Some small, low-quality studies/case series suggest possible benefit of steroids and IVIG; neither clearly has superior or robust evidence. The prompt’s phrase “most evidence-based” is therefore problematic: pain agents like gabapentin have solid evidence for symptom control (though not strength), and both IVIG and steroids are at best experimental/off-label with comparable or weaker evidence. The explanation’s categorical claim that IVIG “has shown benefit” and that plasmapheresis “lacks supporting evidence” oversimplifies a generally low-evidence area, making A not a clearly superior choice to D, and arguably not more evidence-based than optimizing neuropathic pain management.\nMain medical accuracy issues: Overstates IVIG evidence and understates uncertainty around all immunotherapies.\nMinimal fix: Reframe question as “Which investigational immunomodulatory therapy has been reported in small case series to improve pain and strength…?” and keep IVIG as key, or change key/explanation to emphasize limited evidence and focus on pain control (gabapentin).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}]